{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:05:39Z","timestamp":1762272339626,"version":"build-2065373602"},"reference-count":229,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T00:00:00Z","timestamp":1545523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/Multi\/04349\/2013","PTDC\/QUI-OUT\/32243\/2017","PTDC\/QUI-NUC\/30147\/2017","SFRH\/BPD\/97650\/2013","SFRH\/BD\/135915\/2018"],"award-info":[{"award-number":["UID\/Multi\/04349\/2013","PTDC\/QUI-OUT\/32243\/2017","PTDC\/QUI-NUC\/30147\/2017","SFRH\/BPD\/97650\/2013","SFRH\/BD\/135915\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Precision medicine relies on individually tailored therapeutic intervention taking into account individual variability. It is strongly dependent on the availability of target-specific drugs and\/or imaging agents that recognize molecular targets and patient-specific disease mechanisms. The most sensitive molecular imaging modalities, Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), rely on the interaction between an imaging radioprobe and a target. Moreover, the use of target-specific molecular tools for both diagnostics and therapy, theranostic agents, represent an established methodology in nuclear medicine that is assuming an increasingly important role in precision medicine. The design of innovative imaging and\/or theranostic agents is key for further accomplishments in the field. G-protein-coupled receptors (GPCRs), apart from being highly relevant drug targets, have also been largely exploited as molecular targets for non-invasive imaging and\/or systemic radiotherapy of various diseases. Herein, we will discuss recent efforts towards the development of innovative imaging and\/or theranostic agents targeting selected emergent GPCRs, namely the Frizzled receptor (FZD), Ghrelin receptor (GHSR-1a), G protein-coupled estrogen receptor (GPER), and Sphingosine-1-phosphate receptor (S1PR). The pharmacological and clinical relevance will be highlighted, giving particular attention to the studies on the synthesis and characterization of targeted molecular imaging agents, biological evaluation, and potential clinical applications in oncology and non-oncology diseases. Whenever relevant, supporting computational studies will be also discussed.<\/jats:p>","DOI":"10.3390\/molecules24010049","type":"journal-article","created":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T10:37:49Z","timestamp":1545647869000},"page":"49","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-2386","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Franco Machado","sequence":"first","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, CTN, Estrada Nacional 10 (km 139,7), 2695-066 Bobadela LRS, Portugal"},{"name":"Centro de Qu\u00edmica Estrutural, Faculdade de Ci\u00eancias, Universidade de Lisboa, 1749-016 Lisboa, Portugal"}]},{"given":"R\u00faben D.","family":"Silva","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, CTN, Estrada Nacional 10 (km 139,7), 2695-066 Bobadela LRS, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-1007","authenticated-orcid":false,"given":"Rita","family":"Melo","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, CTN, Estrada Nacional 10 (km 139,7), 2695-066 Bobadela LRS, Portugal"},{"name":"Center for Neuroscience and Cell Biology; Rua Larga, Faculdade de Medicina, Polo I, 1\u00baandar, Universidade de Coimbra, 3004-504 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-4906","authenticated-orcid":false,"given":"Jo\u00e3o D.","family":"G. Correia","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, CTN, Estrada Nacional 10 (km 139,7), 2695-066 Bobadela LRS, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2016.10.012","article-title":"Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics","volume":"38","author":"Collins","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.coph.2008.07.007","article-title":"Targeted therapeutics for cancer treatment: Major progress towards personalised molecular medicine","volume":"8","author":"Workman","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrclinonc.2017.186","article-title":"The Evidence Framework for Precision Cancer Medicine","volume":"15","author":"Moscow","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision Medicine\u2014Personalized, Problematic, and Promising","volume":"372","author":"Jameson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Dugger, S.A., Platt, A., and Goldstein, D.B. (2018). Drug development in the era of precision medicine. Nat. Rev. Drug Discov.","DOI":"10.1038\/nrd.2017.226"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2214\/AJR.17.18264","article-title":"Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment","volume":"209","author":"Jadvar","year":"2017","journal-title":"Am. J. Roentgenol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.acra.2016.11.021","article-title":"Role of Imaging in the Era of Precision Medicine","volume":"24","author":"Giardino","year":"2017","journal-title":"Acad. Radiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1148\/radiol.2015150709","article-title":"Imaging in the Age of Precision Medicine: Summary of the Proceedings of the 10th Biannual Symposium of the International Society for Strategic Studies in Radiology","volume":"279","author":"Herold","year":"2016","journal-title":"Radiology"},{"key":"ref_9","first-page":"310","article-title":"Precision medicine and molecular imaging: New targeted approaches toward cancer therapeutic and diagnosis","volume":"6","author":"Ghasemi","year":"2016","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/qjmed\/hcv141","article-title":"Molecular imaging-its current role in cancer","volume":"109","author":"McDermott","year":"2016","journal-title":"QJM Int. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2017.08.002","article-title":"Molecular imaging for precision medicine","volume":"113","author":"Lu","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/cr0782426","article-title":"Molecular imaging with PET","volume":"108","author":"Ametamey","year":"2008","journal-title":"Chem. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-0264","article-title":"Nuclear imaging probes: From bench to bedside","volume":"13","author":"Wester","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.2174\/1389450117666160720091233","article-title":"PET Radiopharmaceuticals for Personalized Medicine","volume":"17","author":"Sharma","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_15","first-page":"297","article-title":"Developing MR Probes for Molecular Imaging","volume":"124","author":"McMahon","year":"2014","journal-title":"Emerg. Appl. Mol. Imaging Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1039\/C4CS00364K","article-title":"Critical design issues in the targeted molecular imaging of cell surface receptors","volume":"44","author":"Sim","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1126\/science.1090585","article-title":"Molecular imaging: Looking at problems, seeing solutions","volume":"302","author":"Herschman","year":"2003","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nature06917","article-title":"Imaging in the era of molecular oncology","volume":"452","author":"Weissleder","year":"2008","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.2147\/OTT.S140671","article-title":"TheranosticsTheranostics in nuclear medicine practice","volume":"10","author":"Yordanova","year":"2017","journal-title":"Oncotargets Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2174\/1874471010666170728094008","article-title":"Personalized & Precision Medicine in Cancer: A Theranostic Approach","volume":"10","author":"Choudhury","year":"2017","journal-title":"Curr. Radiopharm."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Notni, J., and Wester, H.-J. (2018). Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals. J. Label. Compd. Radiopharm.","DOI":"10.1002\/jlcr.3582"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1021\/cr3003104","article-title":"Radiometals for Combined Imaging and Therapy","volume":"113","author":"Cutler","year":"2013","journal-title":"Chem. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ballinger, J.R. (2018). Theranostic radiopharmaceuticals: Established agents in current use. Br. J. Radiol., 91.","DOI":"10.1259\/bjr.20170969"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ahmadzadehfar, H., and Essler, M. (2018). It is time to move forward into the era of Theranostics. Ejnmmi Res., 8.","DOI":"10.1186\/s13550-018-0364-x"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Santos-Cuevas, C., Ferro-Flores, G., Garcia-Perez, F.O., Jimenez-Mancilla, N., Ramirez-Nava, G., Ocampo-Garcia, B., Luna-Gutierrez, M., Azorin-Vega, E., Davanzo, J., and Soldevilla-Gallardo, I. (2018). Lu-177-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer. Contrast Media Mol. Imaging.","DOI":"10.1155\/2018\/5247153"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.116.186841","article-title":"Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?","volume":"58","author":"Eberlein","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.7150\/thno.19782","article-title":"Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry\u2014Technical Review","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2967\/jnumed.116.182188","article-title":"Citius, Altius, Fortius: An Olympian Dream for Theranostics","volume":"58","author":"Hicks","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","article-title":"Ga-68-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis","volume":"58","author":"Graham","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2967\/jnumed.116.186361","article-title":"Current Concepts in Ga-68-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies","volume":"58","author":"Bodei","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_33","first-page":"58","article-title":"Current status of PET imaging of neuroendocrine tumours (18F FDOPA, 68Ga tracers, 11C\/18F-HTP)","volume":"59","author":"Ambrosini","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00259-011-1989-4","article-title":"Ga-68-labelled peptides for diagnosis of gastroenteropancreatic NET","volume":"39","author":"Ambrosini","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00259-011-2019-2","article-title":"Somatostatin receptor SPECT","volume":"39","author":"Pepe","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-015-3027-4","article-title":"Nuclear imaging of neuroendocrine tumors with unknown primary: Why, when and how?","volume":"42","author":"Santhanam","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1874471010666170323115136","article-title":"Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers","volume":"10","author":"Cuccurullo","year":"2017","journal-title":"Curr. Radiopharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40336-016-0193-8","article-title":"Somatostatin receptor PET\/MRI for the evaluation of neuroendocrine tumors","volume":"5","author":"Hope","year":"2017","journal-title":"Clin. Transl. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2967\/jnumed.116.185587","article-title":"The Impact of Somatostatin Receptor-Directed PET\/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis","volume":"58","author":"Barrio","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cives, M., and Strosberg, J. (2017). Radionuclide Therapy for Neuroendocrine Tumors. Curr. Oncol. Rep., 19.","DOI":"10.1007\/s11912-017-0567-8"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.semnuclmed.2009.12.001","article-title":"Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy","volume":"40","author":"Pool","year":"2010","journal-title":"Semin. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrendo.2013.246","article-title":"Neuroendocrine tumours: The role of imaging for diagnosis and therapy","volume":"10","author":"Sundin","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12149-014-0898-6","article-title":"(68)Gallium- and (90)Yttrium-\/(177)Lutetium: \u201ctheranostic twins\u201d for diagnosis and treatment of NETs","volume":"29","author":"Werner","year":"2015","journal-title":"Ann. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2967\/jnumed.117.191528","article-title":"NTR Is the New SSTR? Perspective for Neurotensin Receptor 1 (NTR)-Directed Theranostics","volume":"58","author":"Fendler","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cbdd.13082","article-title":"New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification","volume":"91","author":"Emrarian","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Maschauer, S., and Prante, O. (2017). Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors. J. Label. Compd. Radiopharm.","DOI":"10.1002\/jlcr.3581"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Baum, R.P., Singh, A., Schuchardt, C., Kulkarni, H.R., Klette, I., Wiessalla, S., Osterkamp, F., Reineke, U., and Smerling, C. (2017). 177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma\u2014First clinical results. J. Nucl. Med. Off. Publ. Soc. Nucl. Med.","DOI":"10.2967\/jnumed.117.193847"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Deng, H., Wang, H., Zhang, H., Wang, M., Giglio, B., Ma, X., Jiang, G., Yuan, H., Wu, Z., and Li, Z. (2017). Imaging Neurotensin Receptor in Prostate Cancer with Cu-64-Labeled Neurotensin Analogs. Mol. Imaging, 16.","DOI":"10.1177\/1536012117711369"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"936","DOI":"10.2967\/jnumed.116.185140","article-title":"Proof of Therapeutic Efficacy of a Lu-177-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model","volume":"58","author":"Schulz","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.2967\/jnumed.115.170530","article-title":"Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications","volume":"57","author":"Schulz","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.biopha.2016.12.083","article-title":"Radiolabeled bombesin derivatives for preclinical oncological imaging","volume":"87","author":"Ferreira","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.115.170977","article-title":"Bombesin-Targeted PET of Prostate Cancer","volume":"57","author":"Mansi","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrurol.2013.42","article-title":"Targeting GRPR in urological cancers -from basic research to clinical application","volume":"10","author":"Mansi","year":"2013","journal-title":"Nat. Rev. Urol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/156720111793663624","article-title":"Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status","volume":"8","author":"Sancho","year":"2011","journal-title":"Curr. Drug Deliv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ymeth.2009.04.002","article-title":"Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues","volume":"48","author":"Schroeder","year":"2009","journal-title":"Methods"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.nucmedbio.2017.10.006","article-title":"Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: Cu-64-DOTHA(2)-PEG-RM26","volume":"56","author":"Mansour","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ymeth.2017.07.009","article-title":"New aspects of molecular imaging in prostate cancer","volume":"130","author":"Ceci","year":"2017","journal-title":"Methods"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00259-017-3702-8","article-title":"Diagnosis of recurrent prostate cancer with PET\/CT imaging using the gastrin-releasing peptide receptor antagonist Ga-68-RM2: Preliminary results in patients with negative or inconclusive F-18 Fluoroethylcholine-PET\/CT","volume":"44","author":"Wieser","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cpet.2016.11.003","article-title":"Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin","volume":"12","author":"Sonni","year":"2017","journal-title":"PET Clin."},{"key":"ref_60","first-page":"420","article-title":"New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer","volume":"59","author":"Maffioli","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14728222.2016.1164694","article-title":"Bombesin related peptides\/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment","volume":"20","author":"Moreno","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cpet.2017.02.007","article-title":"Theranostic Prospects of Gastrin-Releasing Peptide Receptor-Radioantagonists in Oncology","volume":"12","author":"Maina","year":"2017","journal-title":"PET Clin."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1158\/1078-0432.CCR-16-2745","article-title":"Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cpet.2016.12.002","article-title":"From Bench to Bed New Gastrin-Releasing Peptide Receptor-Directed Radioligands and Their Use in Prostate Cancer","volume":"12","author":"Maina","year":"2017","journal-title":"PET Clin."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/1874471008666150313112922","article-title":"Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy","volume":"9","author":"Reynolds","year":"2016","journal-title":"Curr. Radiopharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00726-010-0501-y","article-title":"Radiolabeled CCK\/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors","volume":"41","author":"Roosenburg","year":"2011","journal-title":"Amino Acids"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejps.2016.05.011","article-title":"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with In-111-CP04 in medullary thyroid carcinoma patients","volume":"91","author":"Maina","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_68","first-page":"169","article-title":"Distribution, Elimination, and Renal Handling of (99m)Technetium-Demogastrin 1","volume":"27","author":"Trejtnar","year":"2012","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"14605","DOI":"10.18632\/oncotarget.7522","article-title":"Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue","volume":"7","author":"Roy","year":"2016","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2016.01.023","article-title":"From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial","volume":"85","author":"Pawlak","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Kaloudi, A., Nock, B.A., Lymperis, E., Valkema, R., Krenning, E.P., de Jong, M., and Maina, T. (2016). Impact of clinically tested NEP\/ACE inhibitors on tumor uptake of (111)ln-DOTA MG11-first estimates for clinical translation. Ejnmmi Res., 6.","DOI":"10.1186\/s13550-015-0158-3"},{"key":"ref_72","first-page":"20","article-title":"Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon","volume":"31","author":"Kaloudi","year":"2016","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.nucmedbio.2016.03.003","article-title":"Tc-99m-labeled gastrins of varying peptide chain length: Distinct impact of NEP\/ACE-inhibition on stability and tumor uptake in mice","volume":"43","author":"Kaloudi","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"ref_74","first-page":"287","article-title":"Radiolabeled gastrin\/CCK analogs in tumor diagnosis: Towards higher stability and improved tumor targeting","volume":"59","author":"Kaloudi","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2967\/jnumed.113.129411","article-title":"\u201cTo Serve and Protect\u201d: Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting","volume":"55","author":"Nock","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1021\/acsmedchemlett.6b00467","article-title":"Prototypic F-18-Labeled Argininamide-Type Neuropeptide Y Y1R Antagonists as Tracers for PET Imaging of Mammary Carcinoma","volume":"8","author":"Keller","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1021\/acs.molpharmaceut.6b00464","article-title":"Targeting the Neuropeptide Y1 Receptor for Cancer Imaging by Positron Emission Tomography Using Novel Truncated Peptides","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1021\/mp500601z","article-title":"Synthesis and in Vitro and in Vivo Evaluation of an F-18-Labeled Neuropeptide Y Analogue for Imaging of Breast Cancer by PET","volume":"12","author":"Hofmann","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2967\/jnumed.114.142000","article-title":"Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors","volume":"55","author":"Morgat","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2967\/jnumed.113.125351","article-title":"PET Brain Imaging of Neuropeptide Y2 Receptors Using N-C-11-Methyl-JNJ-31020028 in Pigs","volume":"55","author":"Winterdahl","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.neuroimage.2010.11.014","article-title":"Synthesis, characterization, and monkey positron emission tomography (PET) studies of F-18 Y1-973, a PET tracer for the neuropeptide Y Y1 receptor","volume":"54","author":"Hostetler","year":"2011","journal-title":"Neuroimage"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Chatenet, D., Cescato, R., Waser, B., Erchegyi, J., Rivier, J.E., and Reubi, J.C. (2011). Novel dimeric DOTA-coupled peptidic Y-1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers. Ejnmmi Res., 1.","DOI":"10.1186\/2191-219X-1-21"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.bmcl.2009.12.068","article-title":"Lys(DOTA)(4) BVD15, a novel and potent neuropeptide Y analog designed for Y-1 receptor-targeted breast tumor imaging","volume":"20","author":"Guerin","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/anie.200905008","article-title":"Breast-Cancer Diagnosis by Neuropeptide Y Analogues: From Synthesis to Clinical Application","volume":"49","author":"Khan","year":"2010","journal-title":"Angew. Chem.-Int. Ed."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0924-977X(13)70411-5","article-title":"PET brain imaging of neuropeptide Y2 receptors","volume":"23","author":"Smith","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2967\/jnumed.112.106096","article-title":"Targeting of Endothelin Receptors in the Healthy and Infarcted Rat Heart Using the PET Tracer F-18-FBzBMS","volume":"54","author":"Higuchi","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7150\/thno.10900","article-title":"Radionuclide Imaging of Neurohormonal System of the Heart","volume":"5","author":"Chen","year":"2015","journal-title":"Theranostics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1021\/jm101110w","article-title":"Development and Evaluation of Endothelin-A Receptor (Radio)Ligands for Positron Emission Tomography","volume":"54","author":"Michel","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.2174\/092986712803341467","article-title":"Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging","volume":"19","author":"Bai","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2174\/138955709791012210","article-title":"Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities","volume":"9","author":"Holtke","year":"2009","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1016\/j.bmc.2009.08.058","article-title":"PET-compatible endothelin receptor radioligands: Synthesis and first in vitro and in vivo studies","volume":"17","author":"Holtke","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2967\/jnumed.108.051565","article-title":"Synthesis and in vivo evaluation of novel PET radioligands for imaging the endothelin-A receptor","volume":"49","author":"Mathews","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Zhang, C.C., Lin, K.S., and Benard, F. (2017). Molecular Imaging and Radionuclide Therapy of Melanoma Targeting the Melanocortin 1 Receptor. Mol. Imaging, 16.","DOI":"10.1177\/1536012117737919"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7150\/thno.17117","article-title":"Preclinical Melanoma Imaging with Ga-68-Labeled alpha-Melanocyte-Stimulating Hormone Derivatives Using PET","volume":"7","author":"Zhang","year":"2017","journal-title":"Theranostics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2174\/1871520616666161206144414","article-title":"The Effect of A Hexanoic Acid Linker Insertion on the Pharmacokinetics and Tumor Targeting Properties of the Melanoma Imaging Agent 99mTc-HYNIC-cycMSH","volume":"17","author":"Teixeira","year":"2017","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1021\/jm301647t","article-title":"Influence of the Bifunctional Chelator on the Pharmacokinetic Properties of Tc-99m(CO)3-Labeled Cyclic alpha-Melanocyte Stimulating Hormone Analog","volume":"56","author":"Morais","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/bip.21490","article-title":"Melanocortin-1 Receptor-Targeting With Radiolabeled Cyclic alpha-Melanocyte-Stimulating Hormone Analogs for Melanoma Imaging","volume":"94","author":"Raposinho","year":"2010","journal-title":"Biopolymers"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2174\/138920110792246465","article-title":"Molecular Probes for Malignant Melanoma Imaging","volume":"11","author":"Ren","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_99","first-page":"245","article-title":"Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues","volume":"145","author":"Quinn","year":"2010","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejps.2017.06.026","article-title":"Preclinical evaluation of melanocortin-1 receptor (MC1-R) specific Ga-68-and Sc-44-labeled DOTA-NAPamide in melanoma imaging","volume":"106","author":"Nagy","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.nucmedbio.2016.08.014","article-title":"Melanoma targeting with Tc-99m(N)(PNP3)-labeled alpha-melanocyte stimulating hormone peptide analogs: Effects of cyclization on the radiopharmaceutical properties","volume":"43","author":"Carta","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00726-015-2131-x","article-title":"Radiopharmacological characterization of Cu-64-labeled alpha-MSH analogs for potential use in imaging of malignant melanoma","volume":"48","author":"Gao","year":"2016","journal-title":"Amino Acids"},{"key":"ref_103","first-page":"1537","article-title":"Design and Evaluation of Novel Radiolabelled VIP Derivatives for Tumour Targeting","volume":"33","author":"Rangger","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3892\/ijo.2014.2276","article-title":"Vasoactive intestinal peptide receptor- based imaging and treatment of tumors (Review)","volume":"44","author":"Tang","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.nucmedbio.2017.04.007","article-title":"VPAC1 Targeted Cu-64-TP3805 kit preparation and its evaluation","volume":"51","author":"Tripathi","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.urology.2015.10.012","article-title":"VPAC1 Targeted Cu-64-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man","volume":"88","author":"Tripathi","year":"2016","journal-title":"Urology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/jlcr.3038","article-title":"11C-labeled and 18F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain","volume":"56","author":"Funke","year":"2013","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/acschemneuro.5b00268","article-title":"Discovery and Preclinical Validation of C-11 AZ13153556, a Novel Probe for the Histamine Type 3 Receptor","volume":"7","author":"Schou","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Lewis, D.Y., Champion, S., Wyper, D., Dewar, D., and Pimlott, S. (2014). Assessment of I-125 WYE-230949 as a Novel Histamine H-3 Receptor Radiopharmaceutical. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115876"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Koga, K., Maeda, J., Tokunaga, M., Hanyu, M., Kawamura, K., Ohmichi, M., Nakamura, T., Nagai, Y., Seki, C., and Kimura, Y. (2016). Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H-3 receptors. Ejnmmi Res., 6.","DOI":"10.1186\/s13550-016-0170-2"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00259-016-3332-6","article-title":"C-11 TASP457, a novel PET ligand for histamine H-3 receptors in human brain","volume":"43","author":"Kimura","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.nucmedbio.2016.08.004","article-title":"Radiosynthesis and quality control of C-11 TASP457 as a clinically useful PET ligand for imaging of histamine H-3 receptors in human brain","volume":"43","author":"Hanyu","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Nebel, N., Maschauer, S., Kuwert, T., Hocke, C., and Prante, O. (2016). In Vitro and In Vivo Characterization of Selected Fluorine-18 Labeled Radioligands for PET Imaging of the Dopamine D3 Receptor. Molecules, 21.","DOI":"10.3390\/molecules21091144"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/jlcr.3000","article-title":"Radioligands for the dopamine receptor subtypes","volume":"56","author":"Prante","year":"2013","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/j.semnuclmed.2017.05.002","article-title":"Small Molecule Receptor Ligands for PET Studies of the Central Nervous System-Focus on G Protein Coupled Receptors","volume":"47","author":"Mach","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.2174\/092986712802002518","article-title":"Subtype-Selective Dopamine Receptor Radioligands for PET Imaging: Current Status and Recent Developments","volume":"19","author":"Banerjee","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00726-011-1078-9","article-title":"Serotonin and molecular neuroimaging in humans using PET","volume":"42","author":"Saulin","year":"2012","journal-title":"Amino Acids"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/med.20245","article-title":"5-HT radioligands for human brain imaging with PET and SPECT","volume":"33","author":"Paterson","year":"2013","journal-title":"Med. Res. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1021\/acs.bioconjchem.7b00243","article-title":"New Trends and Current Status of Positron-Emission Tomography and Single-Photon-Emission Computerized Tomography Radioligands for Neuronal Serotonin Receptors and Serotonin Transporter","volume":"28","author":"Hazari","year":"2017","journal-title":"Bioconj. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/syn.21835","article-title":"Optimising PET approaches to measuring 5-HT release in human brain","volume":"69","author":"Tyacke","year":"2015","journal-title":"Synapse"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nbd.2013.08.017","article-title":"Translational PET imaging research","volume":"61","author":"Hargreaves","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.drudis.2014.08.012","article-title":"Radiologand development for molecular imaging of the central nervous system with positron emission tomography","volume":"19","author":"Honer","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.semnuclmed.2016.09.001","article-title":"Imaging in Central Nervous System Drug Discovery","volume":"47","author":"Gunn","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Declercq, L.D., Vandenberghe, R., Van Laere, K., Verbruggen, A., and Bormans, G. (2016). Drug Development in Alzheimer\u2019s Disease: The Contribution of PET and SPECT. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00088"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Buiter, H.J.C., Windhorst, A.D., Huisman, M.C., Yaqub, M., Knol, D.L., Fisher, A., Lammertsma, A.A., and Leysen, J.E. (2013). C-11 AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors. Ejnmmi Res., 3.","DOI":"10.1186\/2191-219X-3-19"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.nucmedbio.2011.06.003","article-title":"Imaging of the muscarinic acetylcholine neuroreceptor in rats with the M2 selective agonist F-18 FP-TZTP","volume":"39","author":"Ravasi","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10967-010-0794-z","article-title":"Synthesis of Tc-99m-oxybutynin for M-3-receptor-mediated imaging of urinary bladder","volume":"287","author":"Moustapha","year":"2011","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1139\/V10-149","article-title":"Towards the development of new subtype-specific muscarinic receptor radiopharmaceuticals\u2014Radiosynthesis and ex vivo biodistribution of F-18 3-(4-(2-(2-(2-fluoroethoxy)ethoxy)ethylthio)-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,5,6-tetrahydropyridine","volume":"88","author":"Wilson","year":"2010","journal-title":"Can. J. Chem.-Revue Can. Chim."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4155\/fmc-2016-0213","article-title":"Probing the cholinergic system to understand neurodegenerative diseases","volume":"9","author":"Renard","year":"2017","journal-title":"Futur. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/ml1002458","article-title":"Synthesis and Cardiac Imaging of F-18-Ligands Selective for beta(1)-Adrenoreceptors","volume":"2","author":"Radeke","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2174\/0929867054637608","article-title":"Non-invasive molecular imaging of beta-adrenoceptors in vivo: Perspectives for PET-radioligands","volume":"12","author":"Kopka","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.semnuclmed.2014.05.002","article-title":"Cardiac Molecular Imaging","volume":"44","author":"Wollenweber","year":"2014","journal-title":"Semin. Nucl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00259-014-2899-z","article-title":"Test-retest reliability of C-11-ORM-13070 in PET imaging of alpha(2C)-adrenoceptors in vivo in the human brain","volume":"42","author":"Lehto","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00259-014-2782-y","article-title":"C-11-ORM-13070, a novel PET ligand for brain alpha(2C)-adrenoceptors: Radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men","volume":"41","author":"Luoto","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.113.135574","article-title":"A PET Tracer for Brain alpha(2C) Adrenoceptors, C-11-ORM-13070: Radiosynthesis and Preclinical Evaluation in Rats and Knockout Mice","volume":"55","author":"Arponen","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2174\/156802610793176819","article-title":"Non-Invasive Imaging of the Type 2 Cannabinoid Receptor, Focus on Positron Emission Tomography","volume":"10","author":"Evens","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.2174\/138161208786549380","article-title":"Development of Radioligands for In Vivo Imaging of Type 1 Cannabinoid Receptors (CB1) in Human Brain","volume":"14","author":"Horti","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Navarro, G., Morales, P., Rodriguez-Cueto, C., Fernandez-Ruiz, J., Jagerovic, N., and Franco, R. (2016). Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Front. Neurosci., 10.","DOI":"10.3389\/fnins.2016.00406"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1021\/acs.jmedchem.6b00554","article-title":"Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor","volume":"59","author":"Moldovan","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1021\/acs.molpharmaceut.7b00746","article-title":"From Structure-Activity Relationships on Thiazole Derivatives to the In Vivo Evaluation of a New Radiotracer for Cannabinoid Subtype 2 PET Imaging","volume":"14","author":"Caille","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/acsmedchemlett.7b00129","article-title":"Development of Highly Affine and Selective Fluorinated Cannabinoid Type 2 Receptor Ligands","volume":"8","author":"Moldovan","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Ahamed, M., van Veghel, D., Ullmer, C., Van Laere, K., Verbruggen, A., and Bormans, G.M. (2016). Synthesis, Biodistribution and in vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists C-11 MA2 and F-18 MA3. Front. Neurosci., 10.","DOI":"10.3389\/fnins.2016.00431"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Vuorimaa, A., Rissanen, E., and Airas, L. (2017). In Vivo PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease. Contrast Media Mol. Imaging.","DOI":"10.1155\/2017\/6975841"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-801022-8.00002-7","article-title":"Adenosine Receptor PET Imaging in Human Brain","volume":"119","author":"Mishina","year":"2014","journal-title":"Adenosine Recept. Neurol. Psychiatr."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/med.21432","article-title":"Potential Therapeutic Applications of Adenosine A(2A) Receptor Ligands and Opportunities for A(2A) Receptor Imaging","volume":"38","author":"Dierckx","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1021\/acschemneuro.6b00056","article-title":"In Vivo Imaging of Human Neuroinflammation","volume":"7","author":"Albrecht","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/B978-0-12-801022-8.00011-8","article-title":"Adenosine Receptors and Epilepsy: Current Evidence and Future Potential","volume":"Volume 119","author":"Mori","year":"2014","journal-title":"Adenosine Receptors in Neurology and Psychiatry"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddtec.2017.10.006","article-title":"Imaging the glutamate receptor subtypes-Much achieved, and still much to do","volume":"25","author":"Gruber","year":"2017","journal-title":"Drug Discov. Today Technol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.drudis.2012.10.004","article-title":"PET and SPECT tracers for glutamate receptors","volume":"18","author":"Majo","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/09298673113209990217","article-title":"In Vivo Imaging of the Metabotropic Glutamate Receptor 1 (mGluR1) with Positron Emission Tomography: Recent Advance and Perspective","volume":"21","author":"Li","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1039\/c2cs35085h","article-title":"Imaging agents for the chemokine receptor 4 (CXCR4)","volume":"41","author":"Kuil","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1097\/RLU.0000000000001435","article-title":"Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients","volume":"42","author":"Bluemel","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymeth.2017.09.002","article-title":"Chemokine receptor\u2014Directed imaging and therapy","volume":"130","author":"Buck","year":"2017","journal-title":"Methods"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"96732","DOI":"10.18632\/oncotarget.18235","article-title":"Targeting CXCR4 with 68Ga Pentixafor: A suitable theranostic approach in pleural mesothelioma","volume":"8","author":"Lapa","year":"2017","journal-title":"Oncotarget"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"95606","DOI":"10.18632\/oncotarget.21024","article-title":"Ga-68 pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model\u2014Comparison with F-18 FDG PET\/CT, MRI and ex vivo receptor expression","volume":"8","author":"Schwarzenbok","year":"2017","journal-title":"Oncotarget"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"77S","DOI":"10.2967\/jnumed.116.186874","article-title":"CXCR4 Ligands: The Next Big Hit?","volume":"58","author":"Walenkamp","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00259-017-3622-7","article-title":"68Ga-Pentixafor PET\/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant","volume":"44","author":"Watts","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7150\/thno.18754","article-title":"Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors\u2014A Triple Tracer Comparative Approach","volume":"7","author":"Werner","year":"2017","journal-title":"Theranostics"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood.V128.22.4055.4055","article-title":"Peptide-Receptor Radiotherapy with CXCR4-Targeting Pentixather Reduces Leukemia Burden in Acute Leukemia PDX and Patients","volume":"128","author":"Habringer","year":"2016","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/pr.110.002931","article-title":"International Union of Basic and Clinical Pharmacology. LXXX. The Class Frizzled Receptors","volume":"62","author":"Schulte","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Zeng, C.M., Chen, Z., and Fu, L. (2018). Frizzled Receptors as Potential Therapeutic Targets in Human Cancers. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051543"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.tips.2018.07.001","article-title":"Frizzleds as GPCRs\u2014More Conventional Than We Thought!","volume":"39","author":"Schulte","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_163","first-page":"5859","article-title":"Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray","volume":"62","author":"Nagayama","year":"2002","journal-title":"Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1349-7006.2007.00701.x","article-title":"Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10","volume":"99","author":"Fukukawa","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12149-009-0265-1","article-title":"Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: Therapeutic efficacy largely depends on radiosensitivity","volume":"23","author":"Hanaoka","year":"2009","journal-title":"Ann. Nucl. Med."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Giraudet, A.-L., Cassier, P.A., Iwao-Fukukawa, C., Garin, G., Badel, J.-N., Kryza, D., Chabaud, S., Gilles-Afchain, L., Clapisson, G., and Desuzinges, C. (2018). A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4544-x"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/cas.13636","article-title":"alpha-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.2967\/jnumed.107.049833","article-title":"Direct procedure for the production of At-211-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate","volume":"49","author":"Lindegren","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"91459","DOI":"10.18632\/oncotarget.20665","article-title":"Discovery of novel frizzled-7 inhibitors by targeting the receptor\u2019s transmembrane domain","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1126\/science.1222879","article-title":"Structural Basis of Wnt Recognition by Frizzled","volume":"337","author":"Janda","year":"2012","journal-title":"Science"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35083601","article-title":"Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains","volume":"412","author":"Dann","year":"2001","journal-title":"Nature"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"30596","DOI":"10.1074\/jbc.M115.673202","article-title":"Structure-based Discovery of Novel Small Molecule Wnt Signaling Inhibitors by Targeting the Cysteine-rich Domain of Frizzled","volume":"290","author":"Lee","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/pr.57.4.1","article-title":"International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function","volume":"57","author":"Davenport","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.RES.0000016164.02525.B4","article-title":"CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart","volume":"90","author":"Bodart","year":"2002","journal-title":"Circ. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2004.07.066","article-title":"Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor","volume":"498","author":"Muccioli","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1677\/joe.1.06404","article-title":"Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)\/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a","volume":"188","author":"Delhanty","year":"2006","journal-title":"J. Endocrinol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/en.2003-0899","article-title":"Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor","volume":"145","author":"Thompson","year":"2004","journal-title":"Endocrinology"},{"key":"ref_178","first-page":"47","article-title":"The growth hormone secretagogue receptor","volume":"Volume 77","author":"Litwack","year":"2008","journal-title":"Vitamins and Hormones, Ghrelin"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1021\/jm0001727","article-title":"Structure-function studies on the new growth hormone-releasing peptide, ghrelin: Minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a","volume":"43","author":"Bednarek","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.tem.2017.10.001","article-title":"Ghrelin as a Survival Hormone","volume":"28","author":"Mani","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbcan.2017.02.002","article-title":"Ghrelin and cancer progression","volume":"1868","author":"Lin","year":"2017","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.peptides.2010.08.019","article-title":"Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure","volume":"31","author":"Kreth","year":"2010","journal-title":"Peptides"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjp.0704228","article-title":"I-125-His(9) -Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up-regulation of receptors with atherosclerosis","volume":"134","author":"Katugampola","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"RC7","DOI":"10.1007\/BF03343831","article-title":"Binding of I-125-labeled ghrelin to membranes from human hypothalamus and pituitary gland","volume":"24","author":"Muccioli","year":"2001","journal-title":"J. Endocrinol. Investig."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.brainres.2007.12.055","article-title":"Autoradiographic analysis of ghrelin receptors in the rat hypothalamus","volume":"1196","author":"Harrold","year":"2008","journal-title":"Brain Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MNM.0000000000000790","article-title":"DTPA-(PABn)-Leu(5)-des-acyl ghrelin(1-5) as a new carrier of radionuclides and potential precursor of radiopharmaceuticals","volume":"39","author":"Wojciuk","year":"2018","journal-title":"Nucl. Med. Commun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.nucmedbio.2014.08.012","article-title":"Synthesis and in vitro\/in vivo evaluation of novel mono- and trivalent technetium-99m labeled ghrelin peptide complexes as potential diagnostic radiopharmaceuticals","volume":"42","author":"Kozminski","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1021\/bc2005889","article-title":"Design, Evaluation, and Comparison of Ghrelin Receptor Agonists and Inverse Agonists as Suitable Radiotracers for PET Imaging","volume":"23","author":"Chollet","year":"2012","journal-title":"Bioconj. Chem."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.nucmedbio.2014.05.102","article-title":"Evaluation of Ga-68-DOTA ghrelin (1-19) in LNCaP prostate carcinoma","volume":"41","author":"Carlie","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1021\/acs.jmedchem.7b00164","article-title":"Structure Activity Study of Ghrelin(1-8) Resulting in High Affinity Fluorine-Bearing Ligands for the Ghrelin Receptor","volume":"60","author":"Charron","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/mol.108.049189","article-title":"Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor","volume":"75","author":"Holst","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.regpep.2011.08.011","article-title":"Design and characterization of a fluorescent ghrelin analog for imaging the growth hormone secretagogue receptor 1a","volume":"172","author":"McGirr","year":"2011","journal-title":"Regul. Pept."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pros.21484","article-title":"Ghrelin receptor as a novel imaging target for prostatic neoplasms","volume":"72","author":"Lu","year":"2012","journal-title":"Prostate"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.peptides.2014.01.011","article-title":"Characterization of a far-red analog of ghrelin for imaging GHS-R in P19-derived cardiomyocytes","volume":"54","author":"Douglas","year":"2014","journal-title":"Peptides"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1021\/jm8014519","article-title":"Fluorine and Rhenium Substituted Ghrelin Analogues as Potential Imaging Probes for the Growth Hormone Secretagogue Receptor","volume":"52","author":"Rosita","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.bmc.2011.02.021","article-title":"Synthesis and in vivo evaluation of (S)-6-(4-fluorophenoxy)-3-((1-C-11 methylpiperidin-3-yl)methyl)-2-o-tol ylquinazolin-4(3H)-one, a potential PET tracer for growth hormone secretagogue receptor (GHSR)","volume":"19","author":"Potter","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nucmedbio.2017.06.002","article-title":"Developing new PET tracers to image the growth hormone secretagogue receptor 1a (GHS-R1a)","volume":"52","author":"Kawamura","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1021\/acs.jmedchem.7b01754","article-title":"Development of Candidates for Positron Emission Tomography (PET) Imaging of Ghrelin Receptor in Disease: Design, Synthesis, and Evaluation of Fluorine-Bearing Quinazolinone Derivatives","volume":"61","author":"Hou","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsbmb.2017.03.021","article-title":"Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives","volume":"176","author":"Barton","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/pr.114.009712","article-title":"International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators","volume":"67","author":"Prossnitz","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1126\/science.1106943","article-title":"A transmembrane intracellular estrogen receptor mediates rapid cell signaling","volume":"307","author":"Revankar","year":"2005","journal-title":"Science"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.2174\/092986712801215919","article-title":"Positron Emission Tomography Radiopharmaceuticals for Sex Steroid Hormone Receptor Imaging","volume":"19","author":"Kiyono","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_204","first-page":"4","article-title":"Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone","volume":"59","author":"Talbot","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"E465","DOI":"10.1016\/S1470-2045(13)70292-4","article-title":"PET imaging of oestrogen receptors in patients with breast cancer","volume":"14","author":"Brown","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1021\/ja066360p","article-title":"Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ER alpha\/beta with tridentate pyridin-2-yl hydrazine tricarbonyl-Re\/Tc-99m(I) chelates","volume":"128","author":"Ramesh","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2967\/jnumed.107.048546","article-title":"Preclinical development of a neutral, estrogen receptor-targeted, tridentate Tc-99m(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers","volume":"49","author":"Nayak","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nchembio775","article-title":"Virtual and biomolecular screening converge on a selective agonist for GPR30","volume":"2","author":"Bologa","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nchembio.168","article-title":"In vivo effects of a GPR30 antagonist","volume":"5","author":"Dennis","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/cb1000636","article-title":"Influence of Charge on Cell Permeability and Tumor Imaging of GPR30-Targeted In-111-Labeled Nonsteroidal Imaging Agents","volume":"5","author":"Nayak","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1021\/jm9011802","article-title":"Synthesis and Characterization of Iodinated Tetrahydroquinolines Targeting the G Protein-Coupled Estrogen Receptor GPR30","volume":"53","author":"Ramesh","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Burai, R., Ramesh, C., Nayak, T.K., Dennis, M.K., Bryant, B.K., Prossnitz, E.R., and Arterburn, J.B. (2012). Synthesis and Characterization of Tricarbonyl-Re\/Tc(I) Chelate Probes Targeting the G Protein-Coupled Estrogen Receptor GPER\/GPR30. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046861"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/1541-7786.MCR-14-0289","article-title":"GPER-Targeted, Tc-99m-Labeled, Nonsteroidal Ligands Demonstrate Selective Tumor Imaging and In Vivo Estrogen Binding","volume":"12","author":"Nayak","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1039\/C5OB01827G","article-title":"A Bodipy as a luminescent probe for detection of the G protein estrogen receptor (GPER)","volume":"13","author":"Papalia","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1021\/acs.jmedchem.6b00390","article-title":"Design, Synthesis, and In Vitro and In Vivo Evaluation of an F-18-Labeled Sphingosine 1-Phosphate Receptor 1 (S1P(1)) PET Tracer","volume":"59","author":"Rosenberg","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cmdc.201000477","article-title":"BZM055, an Iodinated Radiotracer Candidate for PET and SPECT Imaging of Myelin and FTY720 Brain Distribution","volume":"6","author":"Briard","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1021\/jm502021d","article-title":"Synthesis and Evaluation of Fluorinated Fingolimod (FTY720) Analogues for Sphingosine-1-Phosphate Receptor Molecular Imaging by Positron Emission Tomography","volume":"58","author":"Shaikh","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1016\/j.bmc.2014.08.009","article-title":"Synthesis of fluorinated analogues of sphingosine-1-phosphate antagonists as potential radiotracers for molecular imaging using positron emission tomography","volume":"22","author":"Prasad","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s12350-015-0391-1","article-title":"A promising carbon-11-labeled sphingosine-1-phosphate receptor 1-specific PET tracer for imaging vascular injury","volume":"24","author":"Jin","year":"2017","journal-title":"J. Nucl. Cardiol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s11307-016-0944-y","article-title":"PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis","volume":"18","author":"Liu","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Liu, H., Jin, H.J., Yue, X.Y., Han, J.B., Baum, P., Abendschein, D.R., and Tu, Z.D. (2017). PET Study of Sphingosine-1-Phosphate Receptor 1 Expression in Response to Vascular Inflammation in a Rat Model of Carotid Injury. Mol. Imaging, 16.","DOI":"10.1177\/1536012116689770"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11307-017-1141-3","article-title":"Upregulated Sphingosine 1-Phosphate Receptor 1 Expression in Human and Murine Atherosclerotic Plaques","volume":"20","author":"Liu","year":"2018","journal-title":"Mol. Imaging Biol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ejmech.2018.03.035","article-title":"Syntheses and in vitro evaluation of new S1PR1 compounds and initial evaluation of a lead F-18 radiotracer in rodents","volume":"150","author":"Luo","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cmdc.201500115","article-title":"MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod)","volume":"10","author":"Briard","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_227","first-page":"S333","article-title":"Brain distribution of MS565, an imaging analogue of siponimod (BAF312), in non-human primates","volume":"261","author":"Tavares","year":"2014","journal-title":"J. Neurol."},{"key":"ref_228","unstructured":"Bhattacharya, S.K., Cameron, K.O.k., Fernando, D.P., Kung, D.W.-S., Londregan, A.T., Mcclure, K.F., and Simila, S.T.M. (2012). 2,3-Dihydro-1H-inden-1-yl-2,7-diazaspiro[3.6] Nonane and Their Use as Antagonists or Inverse Agonists of the Ghrelin Receptor. (WO2011114271A8), WO Application."},{"key":"ref_229","unstructured":"Luyt, L.G., and Fowkes, M.M. (2018). Peptidomimetics for Imaging the Ghrelin Receptor. (15\/578,105), U.S. Patent."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/1\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:35:48Z","timestamp":1760196948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/1\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,23]]},"references-count":229,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1]]}},"alternative-id":["molecules24010049"],"URL":"https:\/\/doi.org\/10.3390\/molecules24010049","relation":{},"ISSN":["1420-3049"],"issn-type":[{"type":"electronic","value":"1420-3049"}],"subject":[],"published":{"date-parts":[[2018,12,23]]}}}